Metropolis Healthcare Limited (METROPOLIS) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

CompoundingAI Research Updated July 30, 2026 3 min read

Metropolis Healthcare enters its Q1 FY2027 results following a business update that signaled strong double-digit revenue growth despite the typical seasonal lull in diagnostic testing. Investors will be watching how the company balances its operating leverage against input cost tailwinds from recent import duty waivers on chemical intermediates.

Quick Details

Results date	August 04, 2026
Quarter	Q1 FY 2026-2027
Previous quarter revenue	Rs. 424.68 Cr
Previous quarter PAT	Rs. 50.96 Cr
Previous quarter EBITDA margin	25.4%
Market cap	Rs. 12,129.99 Cr
CMP	Rs. 585.2

Metropolis Healthcare Limited Q1 Results Date and Time

The company has scheduled a board meeting for August 04, 2026, to consider and approve the audited financial results for the quarter ended June 30, 2026.

What to expect from Metropolis Healthcare Limited's Q1 FY27 results

Metropolis Healthcare is expected to report solid year-over-year revenue growth, supported by the company's own pre-quarter business update of 5 July 2026 which flagged strong performance. While Q1 is seasonally softer than the March-end quarter, acute-testing volumes are likely supported by monsoon-linked infectious disease activity reported in IDSP data. The cost-of-materials ratio is expected to remain in the 18.5–19.5% range, benefiting from the three-month import duty waiver on petrochemical intermediates effective 2 April 2026. Management's medium-term EBITDA margin target of 25–26% remains a key focus, with the Q1 print expected to show moderate year-over-year expansion from the 23.2% margin recorded in Q1 FY2025-26.

Key Things To Watch

Acute test volume vs seasonality

Management commentary on whether Q1 acute-testing matched year-ago levels or benefited from early June outbreak activity

Cost of materials bridge

Explicit mention of import duty savings from the petrochemical exemption
Assessment of whether the cost-of-materials ratio stayed in the 18–19% zone

EBITDA margin trajectory

Guidance reaffirmation on the 25–26% medium-term margin target
Margin performance vs the year-ago 23.2% baseline to set the stepping-stone for FY2026-27

Regulatory update

Status of any GST or HSN-related changes on diagnostic services post-Budget

Frequently Asked Questions

How did Metropolis Healthcare perform in the quarter leading up to this result?

Metropolis Healthcare reported a strong Q1 FY2027 in a business update on 5 July 2026, with consolidated revenue expected to increase by approximately a double-digit percentage. This follows a full-year FY2025-26 where the company achieved an EBITDA margin of 24.4%.

What is the expected impact of import duty waivers on the company's costs?

The government's three-month import duty waiver on critical petrochemical products effective 2 April 2026 provides a modest tailwind to input costs. This is expected to help keep the cost-of-materials ratio in the 18.5–19.5% range, similar to recent quarters.

Is the company's current EBITDA margin in line with its guidance?

The full-year FY2025-26 EBITDA margin of 24.4% sits within the guided medium-term range of 25–26% that management has previously reiterated. Investors will look for further margin expansion from the year-ago Q1 baseline of 23.2%.